Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240984 | 0.87 | KMT2A (0.51) | KMT2AALDH1A1HTTSRD5A2LMNA | |
| SCHEMBL240460 | 0.83 | LMNA (0.59) | KMT2AALDH1A1HTTLMNAPOLB | |
| SCHEMBL14647869 | 0.82 | L3MBTL3 (0.52) | ALDH1A1HTTLMNAHRH3NAMPT | |
| SCHEMBL912597 | 0.82 | L3MBTL3 (0.52) | ALDH1A1HTTLMNAHRH3NAMPT | |
| SCHEMBL239976 | 0.82 | HRH3 (0.48) | KMT2AALDH1A1HTTHRH3POLB | |
| SCHEMBL240534 | 0.81 | PRKAA2 (0.49) | KMT2AALDH1A1HTTNAMPTPOLB | |
| SCHEMBL13047991 | 0.81 | HRH3 (0.48) | KMT2AALDH1A1LMNAHRH3NAMPT | |
| SCHEMBL239977 | 0.81 | KMT2A (0.48) | KMT2AALDH1A1LMNAHRH3POLB | |
| SCHEMBL594897 | 0.80 | SRD5A1 (0.45) | SRD5A2NAMPTSRD5A1 | |
| SCHEMBL594896 | 0.80 | SRD5A1 (0.45) | SRD5A2NAMPTSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | claimed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292215-A1 | 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD17B1 | KMT2A 3848/4885ALDH1A1 67/4885HTT 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.